Role of the ubiquitin proteasome system in renal cell carcinoma

Por Corn, Paul G
Publicado em 2007

The tumor microenvironment in prostate cancer: elucidating molecular pathways for therapy development

Por Corn, Paul G
Publicado em 2012

Identification of a novel prostate cancer biomarker, caveolin-1: Implications and potential clinical benefit

Por Corn, Paul G, Thompson, Timothy C
Publicado em 2010

Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate-resistance and novel therapeutic approaches

Por Karantanos, Theodoros, Corn, Paul G., Thompson, Timothy C.
Publicado em 2013

Novel Therapies for Metastatic Castrate-Resistant Prostate Cancer

Por Dayyani, Farshid, Gallick, Gary E., Logothetis, Christopher J., Corn, Paul G.
Publicado em 2011

Small-molecule protein tyrosine kinase inhibitors for the treatment of metastatic prostate cancer

Por Gallick, Gary E, Corn, Paul G, Zurita, Amado J, Lin, Sue-Hwa
Publicado em 2012

DNA damage response and prostate cancer: defects, regulation and therapeutic implications

Por Karanika, Styliani, Karantanos, Theodoros, Li, Likun, Corn, Paul G., Thompson, Timothy C.
Publicado no Oncogene (2014)

Src signaling pathways in prostate cancer

Por Varkaris, Andreas, Katsiampoura, Anastasia D., Araujo, John C., Gallick, Gary E., Corn, Paul G.
Publicado no Cancer Metastasis Rev (2014)

The Role of HGF/c-Met Signaling in Prostate Cancer Progression and c-Met Inhibitors in Clinical Trials

Por Varkaris, Andreas, Corn, Paul G., Gaur, Sanchaika, Dayyani, Farshid, Logothetis, Christopher J., Gallick, Gary E.
Publicado em 2011

Anti-tumor response to combined anti-angiogenic and cytotoxic chemotherapy in recurrent metastatic chromophobe renal cell carcinoma: Response signatures and Proteomic Correlates

Por Maiti, Abhishek, Brown, Robert E., Corn, Paul G., Murthy, Ravi, Ganeshan, Dhakshina Moorthy, Tsimberidou, Apostolia M., Subbiah, Vivek
Publicado no Clin Genitourin Cancer (2015)

Sunitinib plus androgen deprivation and radiation therapy for patients with localized high-risk prostate cancer: results from a multi-institutional phase I study

Por Corn, Paul G., Song, Danny Y., Heath, Elisabeth, Maier, Jordan, Meyn, Raymond, Kuban, Deborah, DePetrillo, Thomas A., Mathew, Paul
Publicado em 2013

Dasatinib inhibits both osteoclast activation and prostate cancer PC-3 cell-induced osteoclast formation

Por Araujo, John C., Poblenz, Ann, Corn, Paul G., Parikh, Nila U., Starbuck, Michael W., Thompson, Jerry T., Lee, Francis, Logothetis, Christopher J., Darnay, Bryant G.
Publicado em 2009

Phase I trial of sunitinib and temsirolimus in metastatic renal cell carcinoma

Por Campbell, Matthew T., Millikan, Randall E., Altinmakas, Emre, Xiao, Lianchun, Wen, Sin Jen, Siefker-Radtke, Arlene O., Aparicio, Ana, Corn, Paul G., Tannir, Nizar M.
Publicado no Clin Genitourin Cancer (2014)

The combination of serum insulin, osteopontin, and hepatocyte growth factor predicts time to castration-resistant progression in androgen dependent metastatic prostate cancer- an e...

Por Dayyani, Farshid, Zurita, Amado J., Nogueras-González, Graciela M., Slack, Rebecca, Millikan, Randall E., Araujo, John C., Gallick, Gary E., Logothetis, Christopher J., Corn, Paul G.
Publicado no BMC Cancer (2016)

CXCL1 mediates obesity-associated adipose stromal cell trafficking and function in the tumour microenvironment

Por Zhang, Tao, Tseng, Chieh, Zhang, Yan, Sirin, Olga, Corn, Paul G., Li-Ning-Tapia, Elsa M., Troncoso, Patricia, Davis, John, Pettaway, Curtis, Ward, John, Frazier, Marsha L., Logothetis, Christopher, Kolonin, Mikhail G.
Publicado no Nat Commun (2016)

A randomized phase II study of bone-targeted therapy containing strontium-89 in advanced castrate-sensitive prostate cancer

Por Bilen, Mehmet Asim, Johnson, Marcella M., Mathew, Paul, Pagliaro, Lance C., Araujo, John C., Aparicio, Ana, Corn, Paul G., Tannir, Nizar M., Wong, Franklin C., Fisch, Michael J., Logothetis, Christopher, Tu, Shi-Ming
Publicado no Cancer (2014)

Phase II Presurgical Feasibility Study of Bevacizumab in Untreated Patients With Metastatic Renal Cell Carcinoma

Por Jonasch, Eric, Wood, Christopher G., Matin, Surena F., Tu, Shi-Ming, Pagliaro, Lance C., Corn, Paul G., Aparicio, Ana, Tamboli, Pheroze, Millikan, Randall E., Wang, Xuemei, Araujo, John C., Arap, Wadih, Tannir, Nizar
Publicado no J Clin Oncol (2009)

PSA RESPONSE TO NEOADJUVANT ANDROGEN DEPRIVATION THERAPY IS A STRONG INDEPENDENT PREDICTOR OF SURVIVAL IN HIGH-RISK PROSTATE CANCER IN THE DOSE-ESCALATED RADIATION THERAPY ERA

Por McGuire, Sean E., Lee, Andrew K., Cerne, Jasmina Z., Munsell, Mark F., Levy, Lawrence B., Kudchadker, Rajat J., Choi, Seungtaek L., Nguyen, Quynh N., Hoffman, Karen E., Pugh, Thomas J., Frank, Steven J., Corn, Paul G., Logothetis, Christopher J., Kuban, Deborah A.
Publicado em 2012

Caveolin-1 regulates hormone resistance through lipid synthesis, creating novel therapeutic opportunities for castration-resistant prostate cancer

Por Karantanos, Theodoros, Karanika, Styliani, Wang, Jianxiang, Yang, Guang, Dobashi, Masato, Park, Sanghee, Ren, Chengzhen, Li, Likun, Basourakos, Spyridon P., Hoang, Anh, Efstathiou, Eleni, Wang, Xuemei, Troncoso, Patricia, Titus, Mark, Broom, Bradley, Kim, Jeri, Corn, Paul G., Logothetis, Christopher J., Thompson, Timothy C.
Publicado no Oncotarget (2016)

Targeting DNA damage response in prostate cancer through inhibition of androgen receptor/CDC6-ATR-Chk1 signaling: Combined AR/CDC6 and Chk1/2 inhibition for PCa

Por Karanika, Styliani, Karantanos, Theodoros, Li, Likun, Wang, Jianxiang, Park, Sanghee, Yang, Guang, Zuo, Xuemei, Song, Jian H., Maity, Sankar N., Manyam, Ganiraju C., Broom, Bradley, Aparicio, Ana M., Gallick, Gary, Troncoso, Patricia, Corn, Paul G., Navone, Nora, Zhang, Wei, Li, Shuhua, Thompson., Timothy C.
Publicado no Cell Rep (2017)